Landscape of subsequent therapies in perioperative immunotherapy trials across multiple cancer types

Karl Semaan; Rashad Nawfal; Elizabeth Nally; Yelena Y. Janjigian; Caroline Robert; Solange Peters; Thomas Powles; Toni K. Choueiri

doi:10.1016/S1470-2045(24)00513-8

Landscape of subsequent therapies in perioperative immunotherapy trials across multiple cancer types

Karl Semaan, Rashad Nawfal, Elizabeth Nally, Yelena Y. Janjigian, Caroline Robert, Solange Peters, Thomas Powles, Toni K. Choueiri

Résultats de recherche: Contribution à un journal › !!Comment/debate

langue originale	Anglais
Pages (de - à)	161-164
Nombre de pages	4
journal	The Lancet Oncology
Volume	26
Numéro de publication	2
Les DOIs	https://doi.org/10.1016/S1470-2045(24)00513-8
état	Publié - 1 févr. 2025
Modification externe	Oui

Accès au document

10.1016/S1470-2045(24)00513-8

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

@article{d9a91549c5664e8db121e272c60ec436,

title = "Landscape of subsequent therapies in perioperative immunotherapy trials across multiple cancer types",

author = "Karl Semaan and Rashad Nawfal and Elizabeth Nally and Janjigian, {Yelena Y.} and Caroline Robert and Solange Peters and Thomas Powles and Choueiri, {Toni K.}",

year = "2025",

month = feb,

day = "1",

doi = "10.1016/S1470-2045(24)00513-8",

language = "English",

volume = "26",

pages = "161--164",

journal = "The Lancet Oncology",

issn = "1470-2045",

number = "2",

}

TY - JOUR

T1 - Landscape of subsequent therapies in perioperative immunotherapy trials across multiple cancer types

AU - Semaan, Karl

AU - Nawfal, Rashad

AU - Nally, Elizabeth

AU - Janjigian, Yelena Y.

AU - Robert, Caroline

AU - Peters, Solange

AU - Powles, Thomas

AU - Choueiri, Toni K.

PY - 2025/2/1

Y1 - 2025/2/1

UR - http://www.scopus.com/inward/record.url?scp=85216566071&partnerID=8YFLogxK

U2 - 10.1016/S1470-2045(24)00513-8

DO - 10.1016/S1470-2045(24)00513-8

M3 - Comment/debate

C2 - 39510116

AN - SCOPUS:85216566071

SN - 1470-2045

VL - 26

SP - 161

EP - 164

JO - The Lancet Oncology

JF - The Lancet Oncology

IS - 2

ER -